Checkpoint Therapeutics, Inc. (CKPT)

Checkpoint Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	0.04	0.04	0.1	0.19	0.27	1.07
Revenue Growth (YoY)	-39.71%	-60.19%	-46.35%	-28.36%	-74.93%	-37.41%
Cost of Revenue	36.15	36.15	43.57	49.83	48.45	16.35
Gross Profit	-36.11	-36.11	-43.46	-49.63	-48.19	-15.28
Selling, General & Admin	24.97	20.06	8.69	8.7	8.54	7.92
Operating Expenses	20.26	20.06	8.69	8.7	8.54	7.92
Operating Income	-56.38	-56.17	-52.15	-58.33	-56.72	-23.2
Interest & Investment Income	0.01	0.01	0.08	0.16	0.05	0.12
Currency Exchange Gain (Loss)	-0.01	-0	-	-	-	-
Other Non Operating Income (Expenses)	-0.14	-0.07	0.22	-4.45	-	-
Pretax Income	-56.51	-56.24	-51.85	-62.62	-56.67	-23.08
Net Income	-56.51	-56.24	-51.85	-62.62	-56.67	-23.08
Net Income to Common	-56.51	-56.24	-51.85	-62.62	-56.67	-23.08
Shares Outstanding (Basic)	46	40	28	10	8	6
Shares Outstanding (Diluted)	46	40	28	10	8	6
Shares Change (YoY)	30.01%	43.01%	169.69%	21.63%	51.48%	58.14%
EPS (Basic)	-1.22	-1.42	-1.87	-6.09	-6.70	-4.13
EPS (Diluted)	-1.22	-1.42	-1.87	-6.09	-6.70	-4.13
Operating Margin	-137500.00%	-137009.76%	-50629.13%	-30381.77%	-21165.30%	-2170.35%
Profit Margin	-137821.95%	-137170.73%	-50336.89%	-32616.67%	-21145.52%	-2159.12%
EBIT	-56.38	-56.17	-52.15	-58.33	-56.72	-23.2

Updated Mar 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q